Trial reportThe Journal of allergy and clinical immunology2025
Baseline basophil activation and early suppression is associated with clinical outcome after peanut sublingual immunotherapy.
Trial report in The Journal of allergy and clinical immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundSublingual immunotherapy (SLIT) was recently shown to safely induce desensitization and remission of peanut allergy in 1- to 4-year-old children.
objectiveBasophil activation has been shown to be suppressed in allergen-specific immunotherapy. We aimed to evaluate the timing of basophil suppression during peanut SLIT and its impact on clinical outcomes.
methodsA total of 50 children with peanut allergy were enrolled in a peanut SLIT trial and randomized to active peanut or placebo SLIT for 36 months followed by a 3-month avoidance period to evaluate remission. To measure basophil activation by CD63 and CD203c, blood was collected at baseline and again at 12, 24, 36, and 39 months.
resultsFor participants receiving peanut SLIT, basophil activation based on CD63 expression was significantly reduced by 12 months and continued to decrease throughout peanut SLIT, whereas CD63 activation in participants receiving placebo remained unchanged from 0 to 36 months. CD203c expression remained unchanged for both peanut SLIT and placebo participants throughout the trial. Actively treated participants who achieved remission had lower CD63 expression at baseline and significant suppression of CD63 expression by 12 months, whereas participants who failed treatment had higher CD63 expression at baseline and lack of suppression by 12 months. Lower basophil activation in those achieving remission, compared to those who failed treatment, remained present for up to 3 years.
conclusionsFollowing peanut SLIT, participants who achieved remission had significantly suppressed basophil activation by 12 months compared to unsuccessful participants who were not desensitized, suggesting that early suppression of basophils may be indicative of peanut SLIT efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.